Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ESRRB | O95718 | 1/20 | 0.32 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567640 | 0.85 | KCNJ1 (0.66) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL22718951 | 0.85 | KCNJ1 (0.66) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL287273 | 0.80 | KCNJ1 (0.51) | KCNJ1ALDH1A1KCNH2ACHESSTR1 | |
| SCHEMBL286569 | 0.80 | KCNJ1 (0.73) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL286503 | 0.80 | KCNJ1 (0.51) | KCNJ1ALDH1A1KCNH2ACHESSTR1 | |
| SCHEMBL854575 | 0.77 | KCNJ1 (0.46) | KCNJ1ALDH1A1KCNH2ACHESSTR1 | |
| SCHEMBL286632 | 0.76 | KCNJ1 (0.48) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL286450 | 0.76 | KCNJ1 (0.51) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL286640 | 0.76 | KCNJ1 (0.51) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL2729931 | 0.76 | KCNJ1 (0.42) | KCNJ1KCNH2ACHESSTR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976027-B1 | QUINOLINE DERIVATIVES AS FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12304899-B2 | Factor XI activation inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-20220235033-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3976027-A1 | FACTOR XI ACTIVATION INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243049-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-2934533-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2956142-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9604998-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9573961-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2877471-B1 | SPIRO-FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| WO-2014126944-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-08-21 | — | — | WO | disclosed |
| WO-2014099633-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673920-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2014018764-A1 | SPIRO - FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2013090271-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-06-20 | — | — | WO | disclosed |
| EP-2427444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129379-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304899-B2 | Factor XI activation inhibitors | F11, TFPI, F13B | KCNJ1 2770/4885ALDH1A1 2315/4885KCNH2 2681/4885 |
| US-20220235033-A1 | FACTOR XI ACTIVATION INHIBITORS | F11, TFPI, F13B | KCNJ1 2770/4885ALDH1A1 2315/4885KCNH2 2681/4885 |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885ALDH1A1 1376/4885KCNH2 16/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885ALDH1A1 1376/4885KCNH2 16/4885 |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885ALDH1A1 1750/4885KCNH2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.